GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of GeoVax Labs (NASDAQ:GOVX) in a report published on Friday morning,Benzinga reports. They currently have a $18.00 price objective on the stock.

Several other equities research analysts have also recently issued reports on GOVX. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of GeoVax Labs in a research report on Friday, November 15th. Alliance Global Partners began coverage on shares of GeoVax Labs in a research report on Monday, November 11th. They set a “buy” rating and a $15.00 price objective for the company. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $14.20.

GeoVax Labs Stock Down 2.1 %

GeoVax Labs stock opened at $1.91 on Friday. The business’s 50-day moving average price is $2.33 and its 200 day moving average price is $2.74. GeoVax Labs has a 52 week low of $1.09 and a 52 week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.29) by $0.38. The company had revenue of $2.79 million for the quarter, compared to analysts’ expectations of $1.84 million. During the same period in the previous year, the business earned ($4.80) earnings per share. Sell-side analysts forecast that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Hedge Funds Weigh In On GeoVax Labs

An institutional investor recently bought a new position in GeoVax Labs stock. Virtu Financial LLC acquired a new stake in GeoVax Labs, Inc. (NASDAQ:GOVX) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 40,210 shares of the company’s stock, valued at approximately $97,000. Virtu Financial LLC owned about 0.43% of GeoVax Labs at the end of the most recent quarter. Institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.